172 related articles for article (PubMed ID: 6553561)
1. New synthetic inhibitor to the alternative complement pathway.
Ikari N; Sakai Y; Hitomi Y; Fujii S
Immunology; 1983 Aug; 49(4):685-91. PubMed ID: 6553561
[TBL] [Abstract][Full Text] [Related]
2. FUT-175 as a potent inhibitor of C5/C3 convertase activity for production of C5a and C3a.
Inagi R; Miyata T; Maeda K; Sugiyama S; Miyama A; Nakashima I
Immunol Lett; 1991 Jan; 27(1):49-52. PubMed ID: 2019419
[TBL] [Abstract][Full Text] [Related]
3. Characterization of alternative pathway inhibition by a serum derived, low molecular weight complement inhibitor.
Baker PJ; Parker CJ; Osofsky SG
Clin Exp Immunol; 1984 Jan; 55(1):166-76. PubMed ID: 6559107
[TBL] [Abstract][Full Text] [Related]
4. Complement 1 inhibitor is a regulator of the alternative complement pathway.
Jiang H; Wagner E; Zhang H; Frank MM
J Exp Med; 2001 Dec; 194(11):1609-16. PubMed ID: 11733575
[TBL] [Abstract][Full Text] [Related]
5. Hybrid proteins of Cobra Venom Factor and cobra C3: tools to identify functionally important regions in Cobra Venom Factor.
Hew BE; Wehrhahn D; Fritzinger DC; Vogel CW
Toxicon; 2012 Sep; 60(4):632-47. PubMed ID: 22609532
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological studies of FUT-175, nafamstat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments.
Aoyama T; Ino Y; Ozeki M; Oda M; Sato T; Koshiyama Y; Suzuki S; Fujita M
Jpn J Pharmacol; 1984 Jul; 35(3):203-27. PubMed ID: 6482087
[TBL] [Abstract][Full Text] [Related]
7. Identification of intermolecular bonds between human factor B and Cobra Venom Factor important for C3 convertase stability.
Hew BE; Pangburn MK; Vogel CW; Fritzinger DC
Toxicon; 2020 Sep; 184():68-77. PubMed ID: 32526239
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effect of FUT-175 on complement activation and its application for glomerulonephritis with hypocomplementemia.
Fujita Y; Inoue I; Inagi R; Miyata T; Shinzato T; Sugiyama S; Miyama A; Maeda K
Nihon Jinzo Gakkai Shi; 1993 Apr; 35(4):393-7. PubMed ID: 8341019
[TBL] [Abstract][Full Text] [Related]
9. The cobra complement system: I. The alternative pathway of activation.
Vogel CW; Müller-Eberhard HJ
Dev Comp Immunol; 1985; 9(2):311-25. PubMed ID: 3894085
[TBL] [Abstract][Full Text] [Related]
10. Structure and function of recombinant cobra venom factor.
Kock MA; Hew BE; Bammert H; Fritzinger DC; Vogel CW
J Biol Chem; 2004 Jul; 279(29):30836-43. PubMed ID: 15131128
[TBL] [Abstract][Full Text] [Related]
11. Recombinant cobra venom factor.
Vogel CW; Fritzinger DC; Hew BE; Thorne M; Bammert H
Mol Immunol; 2004 Jun; 41(2-3):191-9. PubMed ID: 15159065
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of alternative pathway factor D by factor B-related synthetic hexapeptides.
Lesavre P; Gaillard MH; Halbwachs-Mecarelli L
Eur J Immunol; 1982 Mar; 12(3):252-4. PubMed ID: 6920299
[TBL] [Abstract][Full Text] [Related]
13. Factor D of the alternative pathway of bovine complement: isolation and characterization.
Menger M; Aston WP
Vet Immunol Immunopathol; 1984 Oct; 7(3-4):325-36. PubMed ID: 6568787
[TBL] [Abstract][Full Text] [Related]
14. Identification of functionally important amino acid sequences in cobra venom factor using human C3/Cobra venom factor hybrid proteins.
Hew BE; Fritzinger DC; Pangburn MK; Vogel CW
Toxicon; 2019 Sep; 167():106-116. PubMed ID: 31207349
[TBL] [Abstract][Full Text] [Related]
15. The activation of the alternative pathway C3 convertase by human plasma kallikrein.
DiScipio RG
Immunology; 1982 Mar; 45(3):587-95. PubMed ID: 6916710
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Naja n. naja and Naja h. haje cobra-venom factors: correlation between binding affinity for the fifth component of complement and mediation of its cleavage.
von Zabern I; Hinsch B; Przyklenk H; Schmidt G; Vogt W
Immunobiology; 1980 Dec; 157(4-5):499-514. PubMed ID: 6905795
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of factor H by heparin: a rate-limiting mechanism for inhibition of the alternative complement pathway.
Boackle RJ; Caughman GB; Vesely J; Medgyesi G; Fudenberg HH
Mol Immunol; 1983 Nov; 20(11):1157-64. PubMed ID: 6228720
[TBL] [Abstract][Full Text] [Related]
18. Activated factor B (Bb) of the alternative pathway of complement activation cleaves and activates plasminogen.
Sundsmo JS; Wood LM
J Immunol; 1981 Sep; 127(3):877-80. PubMed ID: 6911148
[TBL] [Abstract][Full Text] [Related]
19. The effect of FUT-175 (Nafamstat Mesilate) on C3a, C4a and C5a generation in vitro and inflammatory reactions in vivo.
Issekutz AC; Roland DM; Patrick RA
Int J Immunopharmacol; 1990; 12(1):1-9. PubMed ID: 2303313
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the classical and alternative pathways of human and guinea pig complement by pyran copolymer.
Webster GF; McArthur WP
Int Arch Allergy Appl Immunol; 1981; 66(3):304-9. PubMed ID: 6913544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
